Business Description
Invex Therapeutics Ltd
ISIN : AU0000048621
Share Class Description:
ASX:IXC: Ordinary SharesDescription
Invex Therapeutics Ltd is a biopharmaceutical company, focused on the research and development of Exenatide as a treatment for neurological conditions such as Idiopathic Intracranial Hypertension (IIH), traumatic brain injury, or acute stroke. Its other program under development is Presendin which can be used for disabling headaches and permanent vision loss in females. Geographically, it operates only in Australia.
Financial Strength
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | No Debt | |||||
Equity-to-Asset | 0.84 | |||||
Interest Coverage | No Debt | |||||
Piotroski F-Score | 3/9 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -25 | |||||
3-Year EPS without NRI Growth Rate | -21.1 | |||||
3-Year FCF Growth Rate | -46.4 | |||||
3-Year Book Growth Rate | -7.9 |
Momentum Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 55.55 | |||||
9-Day RSI | 56.35 | |||||
14-Day RSI | 53.12 | |||||
6-1 Month Momentum % | -13.58 | |||||
12-1 Month Momentum % | -63.16 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 6.38 | |||||
Quick Ratio | 6.38 | |||||
Cash Ratio | 6.25 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Dividend Yield % | 258.75 | |||||
Forward Dividend Yield % | 258.75 | |||||
5-Year Yield-on-Cost % | 258.75 | |||||
3-Year Average Share Buyback Ratio | -3.6 | |||||
Shareholder Yield % | 517.5 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PB Ratio | 1.03 | |||||
Price-to-Tangible-Book | 1.03 | |||||
EV-to-EBIT | 0.11 | |||||
EV-to-EBITDA | 0.11 | |||||
EV-to-FCF | 0.14 | |||||
Price-to-Net-Current-Asset-Value | 1.03 | |||||
Price-to-Net-Cash | 1.03 | |||||
Earnings Yield (Greenblatt) % | 909.09 | |||||
FCF Yield % | -97.41 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Invex Therapeutics Ltd Executives
DetailsGF Value
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil A$) | |||
EPS (TTM) (A$) | -0.08 | ||
Beta | 1.2 | ||
Volatility % | 41.51 | ||
14-Day RSI | 53.12 | ||
14-Day ATR (A$) | 0.001681 | ||
20-Day SMA (A$) | 0.0688 | ||
12-1 Month Momentum % | -63.16 | ||
52-Week Range (A$) | 0.06 - 0.34 | ||
Shares Outstanding (Mil) | 75.15 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 3 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Invex Therapeutics Ltd Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Invex Therapeutics Ltd Stock Events
Event | Date | Price(A$) | ||
---|---|---|---|---|
No Event Data |
Invex Therapeutics Ltd Frequently Asked Questions
What is Invex Therapeutics Ltd(ASX:IXC)'s stock price today?
The current price of ASX:IXC is A$0.07. The 52 week high of ASX:IXC is A$0.34 and 52 week low is A$0.06.
When is next earnings date of Invex Therapeutics Ltd(ASX:IXC)?
The next earnings date of Invex Therapeutics Ltd(ASX:IXC) is .
Does Invex Therapeutics Ltd(ASX:IXC) pay dividends? If so, how much?
The Dividend Yield %  of Invex Therapeutics Ltd(ASX:IXC) is 258.75% (As of Today), Highest Dividend Payout Ratio of Invex Therapeutics Ltd(ASX:IXC) was 0. The lowest was 0. And the median was 0. The  Forward Dividend Yield % of Invex Therapeutics Ltd(ASX:IXC) is 258.75%. For more information regarding to dividend, please check our Dividend Page.
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |